<DOC>
	<DOC>NCT01215409</DOC>
	<brief_summary>In this uncontrolled, non-randomized, prospective, local post-marketed surveillance study, data are obtained on safety and efficacy of LEVITRA® in routine treatment of erectile dysfunction. The general objectives are to evaluate the product safety (primarily by recording adverse events), efficacy and patient acceptance.</brief_summary>
	<brief_title>Real Life Safety and Efficacy of Vardenafil</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<criteria>Any adult patient (&gt;/=18 years) with erectile dysfunction treated with LEVITRA®. Patients must be able to give written informed consent for participation in the study after receiving detailed written and oral information prior to the study. Exclusion criteria must be read in conjunction with the product information (Package Insert).</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Levitra</keyword>
	<keyword>Erectile dysfunction</keyword>
	<keyword>Taiwan</keyword>
</DOC>